CSP EXAM TEST(SPECIALTY PHARMACY)WITH CORRECT ANSWERS!!
PDC calculation - ANSWER: (# of unique days with supply / number of days in a period) x
100
Jak inhibitor - ANSWER: Xeljanz (tofacitinib)
Cholesterol-elevating medication - ANSWER: Actemra (toclizumab) @#
$%^
#$%^&*(
Shingles vaccine safe with TNF inhibitors - ANSWER: Shingrix &*()
Neutropenia risk - ANSWER: Taltz (ixekizumab)
Psoriasis medication without tuberculosis screening - ANSWER: Otezla (apremilast)
Standard starting dose for Taltz (ixekizumab) in psoriatic arthritis - ANSWER: 160mg
subcutaneously once, followed by 80mg subcutaneously every 4 weeks
Medication recommendation for severe dermatitis in a 45 y/o patient - ANSWER: Dupixent
(dupilumab)
Starting dose for Stelara (ustekinumab) in psoriasis - ANSWER: Inject 45 mg
subcutaneously at weeks 0 and 4, followed by 45 mg every 12 weeks
Oral oncology medication without caution in hepatic impairment - ANSWER: Ibrance
(palbociclib)
Non-side effect of Zytiga (abiraterone acetate) - ANSWER: Mucositis
Smoking effect on Tarceva (erlotinib) levels - ANSWER: Smoking decreases Tarceva levels
and the medication will be less effective if he continues to smoke
Oral oncology agents taken with food - ANSWER: Xeloda (capecitabine) and Temodar
(temozolomide)
Recommended oncology treatment for metastatic HER 2+ breast cancer - ANSWER:
Tykerb (lapatinib) in combination with Xeloda (capecitabine)
Incorrect oral chemotherapy cycle - ANSWER: Afinitor (everolimus) 10mg daily for 21 days,
then 7 days off
PDC calculation - ANSWER: (# of unique days with supply / number of days in a period) x
100
Jak inhibitor - ANSWER: Xeljanz (tofacitinib)
Cholesterol-elevating medication - ANSWER: Actemra (toclizumab) @#
$%^
#$%^&*(
Shingles vaccine safe with TNF inhibitors - ANSWER: Shingrix &*()
Neutropenia risk - ANSWER: Taltz (ixekizumab)
Psoriasis medication without tuberculosis screening - ANSWER: Otezla (apremilast)
Standard starting dose for Taltz (ixekizumab) in psoriatic arthritis - ANSWER: 160mg
subcutaneously once, followed by 80mg subcutaneously every 4 weeks
Medication recommendation for severe dermatitis in a 45 y/o patient - ANSWER: Dupixent
(dupilumab)
Starting dose for Stelara (ustekinumab) in psoriasis - ANSWER: Inject 45 mg
subcutaneously at weeks 0 and 4, followed by 45 mg every 12 weeks
Oral oncology medication without caution in hepatic impairment - ANSWER: Ibrance
(palbociclib)
Non-side effect of Zytiga (abiraterone acetate) - ANSWER: Mucositis
Smoking effect on Tarceva (erlotinib) levels - ANSWER: Smoking decreases Tarceva levels
and the medication will be less effective if he continues to smoke
Oral oncology agents taken with food - ANSWER: Xeloda (capecitabine) and Temodar
(temozolomide)
Recommended oncology treatment for metastatic HER 2+ breast cancer - ANSWER:
Tykerb (lapatinib) in combination with Xeloda (capecitabine)
Incorrect oral chemotherapy cycle - ANSWER: Afinitor (everolimus) 10mg daily for 21 days,
then 7 days off
